ProMIS Neurosciences, Inc. (PMN) News
Track canonical SquawkNews coverage tagged to PMN, ProMIS Neurosciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 14 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
ProMIS Neurosciences reports second-quarter 2026 financial results
ProMIS Neurosciences (PMN) announces its second quarter 2026 financial results and provides corporate highlights, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 08:00 PM UTC
L
PMN - ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
PMN - ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
EARNINGS | Aug 03, 2026, 08:00 PM UTC
L
PMN The blinded 6M interim analysis of pooled Ph1 data (drug + pbo) met/exceeded Roth's internal expectations set for safety/ARIA @ Roth
PMN The blinded 6M interim analysis of pooled Ph1 data (drug + pbo) met/exceeded Roth's internal expectations set for safety/ARIA @ Roth
EQUITY | Jul 28, 2026, 12:25 PM UTC
H
Market-Moving News for July 28th
AMKR: -9% | Amkor Technology shares are trading lower after the company reported Q2 financial results and issued Q3 sales guidance below estimates. PMN: 32% | ProMIS Neurosciences shares are trading higher after the comp
EARNINGS | Jul 28, 2026, 11:21 AM UTC
L
PMN Promis Neurosciences is trying to Design a safer amyloid-clearing drug for Alzheimer's. Early results suggest it might be on to somethin
PMN Promis Neurosciences is trying to Design a safer amyloid-clearing drug for Alzheimer's. Early results suggest it might be on to something - STAT News Link To Story from STATNEWS.com; shares+10% premarket
EQUITY | Jul 28, 2026, 10:39 AM UTC
L
These early $PMN safety data — 4% total ARIA rate — should get attention today: ProMIS preliminary trial results suggest a path
These early $PMN safety data — 4% total ARIA rate — should get attention today: ProMIS preliminary trial results suggest a path to a safer Alzheimer’s treatment Adam F X post
EQUITY | Jul 28, 2026, 10:22 AM UTC
L
PMN - ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzhei
PMN - ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
EQUITY | Jul 28, 2026, 10:00 AM UTC
L
PMN - ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzh
PMN - ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
EQUITY | Jul 27, 2026, 08:00 PM UTC
L
PMN new Buy W/ $20 PT @ Chardan
PMN new Buy W/ $20 PT @ Chardan
EQUITY | Jul 27, 2026, 11:49 AM UTC
L
Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: O
Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: OVERWEIGHT @ JPM CLH ITG: BUY @ BAC ARLO WSM: OVERWEIGHT @ Piper ADUR: BUY @ ROTH
EQUITY | Jul 27, 2026, 11:09 AM UTC
L
PMN PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy v
PMN PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers Represents one of the first quantitative measures of treatment-related
EQUITY | Jul 14, 2026, 10:48 AM UTC
L
ProMIS Neurosciences shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating.
ProMIS Neurosciences shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating.
EQUITY | Jun 30, 2026, 06:07 PM UTC
L
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Creative Medical Tech (NASDAQ: CELZ ) stock moved upwards by 242.5% to $2.77 during Tuesday's regular session. The market value of their outstanding shares is at $2.9 million. Cuprina Holdings (Cayman) (NASDAQ: C
EQUITY | Jun 30, 2026, 05:05 PM UTC
L
Cantor Fitzgerald Initiates Coverage On ProMIS Neurosciences with Overweight Rating
Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on ProMIS Neurosciences (NASDAQ: PMN ) with a Overweight rating.
EQUITY | Jun 30, 2026, 01:32 PM UTC